Abstract
Pulmonary arterial hypertension (PAH) is a rare, incurable disease characterized by adverse remodeling of the pulmonary vasculature, leading to increased pulmonary arterial pressures and right ventricular failure. Contemporary pharmacotherapy targets 3 distinct molecular pathways that are abnormal in PAH: deficient production of nitric oxide and prostacyclin, and over production of endothelin. Risk assessment is critical in guiding therapeutic decision making and in disease surveillance following treatment initiation. Patients with more advanced disease are best treated with continuous infusion therapy, while those less symptomatic patients may respond to oral or inhaled therapies. Combination therapy is being increasingly utilized in patients who fail to achieve treatment goals.
Keywords: Pulmonary hypertension, pulmonary arterial hypertension, right ventricle failure, prostacyclins, endothelin receptor antagonist.
Current Pharmaceutical Design
Title:Pharmacologic Treatment of Pulmonary Arterial Hypertension
Volume: 19 Issue: 22
Author(s): Gautam V. Ramani and Sartraj Gill
Affiliation:
Keywords: Pulmonary hypertension, pulmonary arterial hypertension, right ventricle failure, prostacyclins, endothelin receptor antagonist.
Abstract: Pulmonary arterial hypertension (PAH) is a rare, incurable disease characterized by adverse remodeling of the pulmonary vasculature, leading to increased pulmonary arterial pressures and right ventricular failure. Contemporary pharmacotherapy targets 3 distinct molecular pathways that are abnormal in PAH: deficient production of nitric oxide and prostacyclin, and over production of endothelin. Risk assessment is critical in guiding therapeutic decision making and in disease surveillance following treatment initiation. Patients with more advanced disease are best treated with continuous infusion therapy, while those less symptomatic patients may respond to oral or inhaled therapies. Combination therapy is being increasingly utilized in patients who fail to achieve treatment goals.
Export Options
About this article
Cite this article as:
V. Ramani Gautam and Gill Sartraj, Pharmacologic Treatment of Pulmonary Arterial Hypertension, Current Pharmaceutical Design 2013; 19 (22) . https://dx.doi.org/10.2174/1381612811319220004
DOI https://dx.doi.org/10.2174/1381612811319220004 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prognostic Value of White Blood Cell Counts and C-reactive Protein in Acute Ischemic Stroke Patients After Intravenous Thrombolysis
Current Neurovascular Research Editorial [Hot Topic: G-Protein-Coupled Receptors (GPCRs) and Drug Discovery (Guest Editor: Luca Gentilucci)]
Current Drug Targets Vitexin with its Derivatives is Responsible for the Cholinomimetic Properties of <i>Penianthus longifolius</i> Extract which Stimulates Muscarinic Receptors
The Natural Products Journal Is Metabolic Syndrome X a Disorder of the Brain?
Current Nutrition & Food Science MicroRNAs: A Critical Regulator and a Promising Therapeutic and Diagnostic Molecule for Diabetic Cardiomyopathy
Current Gene Therapy Diabetes and Heart Failure: Is it Hyperglycemia or Hyperinsulinemia?
Current Vascular Pharmacology Tetrahydrobiopterin: A Vascular Redox Target to Improve Endothelial Function
Current Vascular Pharmacology (Neuro)Transmitter Systems in Circulating Immune Cells: A Target of Immunopharmacological Interventions?
Current Medicinal Chemistry Oxidative Stress Drivers and Modulators in Obesity and Cardiovascular Disease: From Biomarkers to Therapeutic Approach
Current Medicinal Chemistry The Impact of Comorbid Diabetes Type 2 on Quality of Life in Cancer Patients Undergoing Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Association of Neutrophil-Lymphocyte Ratio with Mild Cognitive Impairment in Elderly Chinese Adults: A Case-control Study
Current Alzheimer Research Presence of Distinct Virtual Backbone Torsion angles in Dipeptide Conformers
Protein & Peptide Letters Hypotensive Agents from Snake Venoms
Current Drug Targets - Cardiovascular & Hematological Disorders Interactions Between Advanced Glycation End-Products (AGE) and their Receptors in the Development and Progression of Diabetic Nephropathy – are these Receptors Valid Therapeutic Targets
Current Drug Targets Interstitial Lung Disease Associated with Polymyositis-Dermatomyositis
Current Respiratory Medicine Reviews Selective Serotonin Reuptake Inhibitors in Pregnancy
Current Medicinal Chemistry Targeting New Pharmacological Approaches for Alzheimer’s Disease: Potential for Statins and Phosphodiesterase Inhibitors
CNS & Neurological Disorders - Drug Targets C-type Natriuretic Peptide (CNP): Cardiovascular Roles and Potential as a Therapeutic Target
Current Pharmaceutical Design Editorial [Hot topic: The Challenge of Prescribing Drugs in Older People (Guest Editors: Fabrizia Lattanzio and Andrea Corsonello)]
Current Drug Metabolism Role of Translocator Protein in Renal Ischemia Reperfusion, Renal Preservation and Acute Kidney Injury
Current Molecular Medicine